Table 2.
BMD and PMA association with clinical outcomes in COPDGene study participants with mild to very severe COPD (N = 4248)
| Outcome1 | BMD | PMA | ||||
|---|---|---|---|---|---|---|
| 95% CI | p-value | 95% CI | p-value | |||
| Clinical outcomes | ||||||
| Handgrip Strength (kg)* | 0.03 | (0.001, 0.05) | 0.045 | 0.20 | (0.10, 0.31) | < 0.001 |
| Emphysema (%) | − 0.07 | (− 0.08, − 0.06) | < 0.001 | − 0.40 | (− 0.42, − 0.35) | < 0.001 |
| 6MWD (m) | 0.17 | (0.09, 0.25) | < 0.001 | 1.20 | (0.83, 1.60) | < 0.001 |
| FEV1pp | 0.09 | (0.07, 0.10) | < 0.001 | 0.51 | (0.44, 0.57) | < 0.001 |
| CRP (mg/dL)** | 0.0038 | (0.0012, 0.0065) | 0.0045 | − 0.012 | (− 0.02, 0.0007) | 0.064 |
BMD, bone mineral density; BMI, Body Mass Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C-Reactive Protein; FEV1pp, forced expiratory volume in 1 s percent predicted; PMA, pectoralis muscle area; KG, Kilograms; 6MWD, 6-min walk distance (m)
1Models were adjusted for pack years, sex, number of comorbidities (cancer, diabetes, heart disease, and gastroesophageal reflux disease), severe exacerbations, and categorical BMI. 6MWD was additionally adjusted for height
*Handgrip strength was only available in a small subset of participants with COPD (N = ???)
**CRP was only available in a small subset of participants with COPD (N = 347)